NasdaqCM - Delayed Quote USD

SELLAS Life Sciences Group, Inc. (SLS)

1.4600 -0.0600 (-3.95%)
At close: April 26 at 4:00 PM EDT
1.4600 0.00 (0.00%)
After hours: April 26 at 7:23 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Angelos M. Stergiou M.D., ScD h.c. Founder, President, CEO & Director 921.99k -- 1976
Mr. John Thomas Burns CPA Senior VP & CFO 338.45k -- 1985
Ms. Stacy E. Yeung VP, Associate General Counsel & Head of Compliance -- -- --
Dr. Dragan Cicic M.D., MBA Senior Vice President of Clinical Development 466.43k -- 1963
Mr. Andrew Elnatan VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality -- -- --

SELLAS Life Sciences Group, Inc.

Times Square Tower
Suite 2503 7 Times Square
New York, NY 10036
United States
646 200 5278 https://www.sellaslifesciences.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
16

Description

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Corporate Governance

SELLAS Life Sciences Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
SELLAS Life Sciences Group, Inc. Earnings Call

Related Tickers

ICU SeaStar Medical Holding Corporation
0.4402
-8.63%
 
XFOR X4 Pharmaceuticals, Inc.
1.1650
+3.10%
 
GLSI Greenwich LifeSciences, Inc.
13.12
+6.32%
 
ATOS Atossa Therapeutics, Inc.
1.5300
+0.66%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%
 
AKBA Akebia Therapeutics, Inc.
1.3400
+0.75%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9900
+0.34%
 
VINC Vincerx Pharma, Inc.
0.7300
-18.59%
 
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
 
TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%